Pfizer (PFE) Stock Price & Analysis
PFE Stock Chart & Stats
- Day’s Range
- MXN 560.06 - MXN 579.60
- 52-Week Range
- MXN 413.00 - MXN 579.60
- Previous Close
- MXN 560.01
- Volume
- 276
- Average Volume (3M)
- 2,153
- Market Cap
- MXN 3.27T
- Enterprise Value
- MXN 190.23B
- Total Cash (Recent Filing)
- MXN 11.70B
- Total Debt (Recent Filing)
- MXN 63.19B
- Price to Earnings (P/E)
- 40.3
- Beta
- 0.10
- Next Earnings
- Nov 03, 2026 (Est.)
- EPS Estimate
- 13.7
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 5.27%
Bulls Say, Bears Say
Bulls Say
Launched And Acquired Product Growth
Strong growth from launched and acquired products shows Pfizer is rebuilding its commercial base beyond legacy and COVID products. Expanding contributions from Seagen assets and other brands can support more durable revenue growth, improve portfolio mix, and help offset future patent-related declines.
Pipeline Productivity And Clinical Breadth
A broad stream of approvals, readouts, and pivotal study starts increases the probability that Pfizer can replenish its product portfolio over time. Progress across oncology, obesity, immunology, and other areas supports long-term diversification and reduces reliance on individual mature medicines.
Manufacturing Savings And Operating Discipline
The expanded savings program offers a multi-year opportunity to protect margins and cash generation while Pfizer invests in research and business development. Manufacturing optimization and broader cost realignment could improve efficiency and provide greater flexibility during the loss-of-exclusivity transition.
Bears Say
Elevated Leverage During The LOE Transition
Leverage near 2.7x limits financial flexibility as Pfizer faces upcoming loss-of-exclusivity events and continued investment needs. If cash flow weakens during the transition, a heavier debt burden could constrain acquisitions, research spending, shareholder returns, and the pace of portfolio renewal.
Clinical Execution Setback
The Phase III miss demonstrates that substantial research investment may not translate into approvals or commercial products, creating uncertainty around pipeline replacement. The associated impairment also reduces the value of an acquired asset and highlights execution risk in oncology development.
Asset And Revenue Disruption From Oxbryta
Removing Oxbryta from revenue expectations weakens the near-term contribution from that asset and signals regulatory uncertainty can materially alter portfolio economics. The related impairment reinforces the risk that product assumptions and acquired-asset values may need further revision.
Pfizer News
PFE FAQ
What was Pfizer’s price range in the past 12 months?
What is Pfizer’s market cap?
When is Pfizer’s upcoming earnings report date?
How were Pfizer’s earnings last quarter?
Is Pfizer overvalued?
Does Pfizer pay dividends?
What is Pfizer’s EPS estimate?
How many shares outstanding does Pfizer have?
What happened to Pfizer’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Pfizer?
What is the TipRanks Smart Score and how is it calculated?
Pfizer Stock Smart Score
Company Description
Pfizer
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla
- Employees
- 75,000
- Website
- www.pfizer.com
- Address
- 66 Hudson Boulevard East, New York City, NY, 10001-2192, US
Pfizer (PFE) Earnings & Revenues
PFE Company Deck
PFE Earnings Call
Earnings Call SentimentPositive
The call conveyed a generally positive operational and strategic narrative: management beat Q2 revenue and adjusted EPS expectations, raised full-year revenue guidance, highlighted strong growth across launched and acquired products (notably Seagen assets, Padcev, NURTEC, and Eliquis), and outlined robust R&D progress (numerous readouts, pivotal starts and promising clinical data across obesity, oncology and immunology). At the same time, material near-term setbacks were disclosed: a Phase III SV miss that drove a $4.3 billion impairment and a GAAP loss, lower-than-expected COVID revenues (notably Paxlovid), removal of Oxbryta revenue from forecasts, and elevated near-term R&D spend. Management emphasized cost-savings initiatives (now targeting ~ $9.7B through 2029), maintained dividend commitments, and raised confidence in returning to growth by the end of the decade. Overall, positives (revenue/EPS beats, guidance raise, strong launched/acquired product growth, and significant pipeline progress) outweigh the material but specific negatives tied largely to one clinical readout and COVID variability.
View all MX:PFE earnings summariesPFE Net sales Breakdown
- 97.79% Biopharma
- 0.00% PC1
- 0.00% Pfizer Ignite
- 2.21% Other business activities
PFE Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 3 | 5 |
| Technical Analysis | 2 | 3 | 5 |
| Moving Averages | 12 | 0 | 0 |